April 2019

Mortality Marker Pinpointed for Dermatomyositis

A recent study completed by researchers from Rouen University Hospital in France has identified IgG2 isotype of the autoantibody anti-TIF1y, as a bio-marker in predicting cancer and mortality among patients with dermatomyositis (DM). The study found that compared with DM patients who were negative for the marker, patients who were positive for anti-TIF1 lgG2 had nearly triple the risk of cancer, with a hazard ratio of 3.1 (95% CI 1.5-6.5). The study’s authors highlighted the importance of the findings, explaining: “As cancer is the major risk of mortality in adult DM and complicates the therapeutic management of DM, there is a need to identify tools that may help to evaluate the risk of cancer and mortality in anti-TIF1γ+ adult DM patients, and to decide how long and how much cancer screening should be proposed for an individual patient."

Hoth Therapeutics, Inc. Announces the Addition of Lawrence A. Schachner, M.D. to its Scientific Advisory Board

Biopharmaceutical company Hoth Therapeutics has recently announced the addition of Lawrence A. Schachner, MD and Vincent C.O. Njar, Ph.D. to the company’s scientific advisory board tasked with assisting the development of the BioLexa platform and other therapeutics. As a leading biopharmaceutical company focused on advanced targeted therapies for patients suffering from skin conditions including atopic dermatitis and chronic wound disorders, Hoth Therapeutics is moving towards its next phase in its proprietary, patented, drug compound BioLexa Platform. In a publicly released statement, Robb Knie, CEO of Hoth Therapeutics commented, "I am pleased to welcome both Dr. Schachner and Dr. Njar to our Scientific Advisory Board. As we move toward clinical trials, the company is fortunate to have such well respected leaders adding their expertise and insight."

FDA Approves Corticosteroid-Retinoid Lotion for Plaque Psoriasis

The Food and Drug Administration recently approved a topical combination of corticosteroid halobetasol propionate (0.01%) and the topical retinoid , tazarotene (0.045%) in a lotion formulated for the treatment of plaque psoriasis in adults. In a press release, the company Ortho Dermatologics outlines the promising results from two phase 3 studies that compared treatment against the combination product. The approved product will be marketed under the name Duobrii and will be priced at $825 for a 100-gram tube.    
Put your dermatological knowledge to the test while gaining CME credit hours through our newly updated CME Library. With 5 new online activities designed for active practitioners, our online CME library serves to allow you to remain up-to-date on the latest clinical trends and guidelines.

Immunotherapy for advanced cutaneous squamous cell carcinoma works by Interleukin-6 (IL-6) inhibition.
Find the answer while gaining CME credits through our extensive online CME library designed for your convenience.
As a world-renowned and board-certified aesthetic plastic surgeon, Dr. Lorenc has long served as a leading force in acute aesthetic surgery. A pioneer in the development of the latest generation of dermal fillers and neurotoxins, Dr. Lorenc is responsible for many breakthroughs in aesthetic medicine including a patent for the bio-absorbable soft tissue suspension device and FDA approval of the leading facial filler, Restylane®. As SBS prepares for our 2020 event, Dr. Lorenc serves a key role in creating a program strategically grounded in the latest and most effective research, knowledge, and techniques capable of providing your patients with the highest levels of satisfaction.
Allergies are one of the most common chronic diseases, affecting up to 30% of U.S. adults. In industrial cities, the problem increases, with nearly one in three people suffering from allergies at some point in their lives.
View this email in your browser
This is an educational message from SBS.
1801 N. Military Trail, Suite 200 • Boca Raton, FL 33431 • 561-997-0112
You are subscribed to this newsletter with the email address %user_email%.
To unsubscribe click here.